| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028989702 |
| P356 | DOI | 10.2165/00019053-200624110-00006 |
| P698 | PubMed publication ID | 17067194 |
| P2093 | author name string | Mark J Sculpher | |
| Michael F Drummond | |||
| P2860 | cites work | Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence? | Q81037141 |
| The use of probabilistic decision models in technology assessment : the case of total hip replacement | Q81385375 | ||
| National Institute for Clinical Excellence and its value judgments | Q24562214 | ||
| Assessing the appropriateness of combining economic data from multinational clinical trials | Q30802399 | ||
| Using multilevel models for assessing the variability of multinational resource use and cost data. | Q30961875 | ||
| Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions | Q31058011 | ||
| 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data | Q33261643 | ||
| Health economic guidelines--similarities, differences and some implications | Q34436165 | ||
| Generalisability in economic evaluation studies in healthcare: a review and case studies. | Q35950554 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Using value of information analysis to prioritise health research: some lessons from recent UK experience | Q36635492 | ||
| Whither trial-based economic evaluation for health care decision making? | Q40349299 | ||
| A rational framework for decision making by the National Institute For Clinical Excellence (NICE). | Q40632683 | ||
| Research into the use of health economics in decision making in the United Kingdom--Phase II. Is health economics 'for good or evil'? | Q40811826 | ||
| Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction | Q40985280 | ||
| Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis | Q45247322 | ||
| Estimating country-specific cost-effectiveness from multinational clinical trials | Q47744065 | ||
| Cost-effectiveness analysis for multinational clinical trials | Q50133311 | ||
| Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities. | Q50515872 | ||
| Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study. | Q52072478 | ||
| Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? | Q56458776 | ||
| Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra | Q61856226 | ||
| Analyzing differences in the costs of treatment across centers within economic evaluations. | Q64904384 | ||
| The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies | Q73122940 | ||
| Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models | Q80603253 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1087-1099 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? | |
| P478 | volume | 24 |
| Q35820527 | A Time-Trend Economic Analysis of Cancer Drug Trials |
| Q38074914 | A systematic and critical review of the evolving methods and applications of value of information in academia and practice. |
| Q48583320 | A systematic review of pharmacoeconomic guidelines |
| Q37627235 | Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region |
| Q79304976 | Better analysis for better decisions: facing up to the challenges |
| Q30491297 | Can economic evaluation in telemedicine be trusted? A systematic review of the literature |
| Q33955955 | Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. |
| Q38153807 | Economic evaluations in European reimbursement submission guidelines: current status and comparisons. |
| Q39614547 | Health technology assessment in Poland and Scotland: comparison of process and decisions |
| Q38068886 | Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report |
| Q81581696 | Key principles for the improved conduct of health technology assessments for resource allocation decisions |
| Q82459574 | Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands |
| Q33772852 | Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development |
| Q37588121 | Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice. |
| Q34804377 | Reimbursement of pharmaceuticals: reference pricing versus health technology assessment |
| Q30382232 | Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessment |
| Q37451168 | Systematic reviews of economic evaluations: utility or futility? |
| Q36490234 | The use of cost-effectiveness analysis for pediatric immunization in developing countries |
| Q51157350 | [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment]. |
Search more.